COMPANY PROFILE

Luna Diabetes

Luna was formed to bring the incredible and life-changing benefits of automated insulin delivery to those that use insulin pens

San Diego, United StatesFounded 2020Health Tech & Medtech

Valuation $100–250M Last recorded · 2025

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Luna Diabetes

Luna Health Inc. is a pioneering company in the diabetes care industry, focusing on developing advanced automated insulin delivery systems. The company's primary product is an investigational device designed to simplify and improve the management of diabetes for insulin pen users. Luna Health serves individuals with diabetes who rely on insulin pens, offering them the benefits of an insulin pump without the associated complexities. Operating in the healthcare technology market, Luna Health's business model revolves around innovation and patient-centric solutions. The company aims to generate revenue through the eventual commercial sale of its FDA-cleared devices, which are currently under investigational use as per federal regulations. Luna Health's approach combines cutting-edge technology with user-friendly design to enhance the quality of life for diabetes patients.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2020
Headquarters: San Diego, United States
Employees: 18
Open positions: 1
Dealroom signal: 84.8/100
Industry: Health
Sub-industry: Medical Devices
Sector: Health Tech & Medtech, Diabetes, Wearable, Hard Tech, DT and LS, science-based
Technology: Artificial Intelligence, Deep Tech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Aug 2025	$24M	$94M	Vensana Capital · Winklevoss Capital · Ascensia Diabetes Care · Swiss Diabetes Venture Fund	↗

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Luna Diabetes website traffic

Latest recorded traffic for Luna Diabetes is 3K monthly website visits, up 25% over the last three months. Luna Diabetes's team grew 20% over the past year.

Latest monthly visits3K 3-month web change+25% 1-year team growth+20%

Monthly website visitsMay 2023–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Director of SoftwareSan Diego, California, United States, Northern America, Americas · Backend Development · Aug 14, 2026 Senior Quality EngineerSan Diego, California, United States, Northern America, Americas · Other · Jul 30, 2026

2 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
STShennapsi Artificial Intelligence TechnologyA developer and manufacturer of AI-powered medical-grade smart wearable devices	Dongcheng District, China	Operational	—	—	—
D.D.SoleA smart foot insole for early detection of diabetic foot complications	Pittsburgh, United States	Operational
U-U-PumpAI-powered, reusable insulin patch pump making diabetes therapy 80% more affordable, accessible, and patient-friendly	Crockett, United States	Operational
QOQuantum OperationWearable sensor for non-invasive, continuous glucose monitoring	Tokyo, Japan	Operational
INInfinovoInnovative medical device manufacturer	Suzhou Shi, China	Operational
SISirenDeveloper of a diabetic foot monitoring system used to detect and treat diabetics	San Francisco, United States	Operational
BBBigfoot BiomedicalA new kind of medical device company developing technologies to significantly reduce the cognitive, emotional, and financial burden of insulin-requiring diabetes	Milpitas, United States	Acquired
MEMedicsenNeedle-free drug delivery platform based on sonophoresis (ultrasounds) to replace needles and cannulas in the transdermal delivery of large molecules	Madrid, Spain	Operational